Regulating Together in Tuberous Sclerosis Complex
Launched by UNIVERSITY OF ROCHESTER · Oct 23, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Regulating Together in Tuberous Sclerosis Complex" is exploring a program called Regulating Together (RT). This program is designed to help children and teenagers with Tuberous Sclerosis Complex (TSC) and related behavioral challenges, such as temper tantrums, aggressive outbursts, and impulsive actions. The goal is to provide a remote treatment option that doesn't involve medication, making it more accessible for families.
To participate, children aged 8 to 17 who have been diagnosed with TSC and show signs of behavioral difficulties may be eligible. It's important that they, along with their caregivers, can communicate in English and have access to a device with video capabilities and a stable internet connection. The study is currently looking for participants, and if families face challenges with technology access, help will be provided to connect them with resources. Throughout the trial, participants will attend treatment sessions designed to improve emotional regulation skills. However, those on certain medications or with specific disruptive behaviors may not qualify. This trial aims to make a positive impact on the lives of children with TSC and their families by providing valuable support and tools for managing emotions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children ages 8-17 years inclusive with a documented clinical and/or genetic diagnosis of TSC and exhibiting symptoms of behavioral dysregulation (identified on the TAND Checklist having temper tantrums, aggressive outbursts, self-injury, and/or impulsivity) are eligible for inclusion.
- Additional inclusion/eligibility criteria include:
- • Participants and their caregivers have access to a computer, phone, or tablet with video capability and stable internet connection. If lack of a device or internet service is the sole barrier to eligibility/participation, interested individuals will be connected to a TSC Clinic social worker to link them to existing government and charity programs specifically addressing this disparity in underserved communities and households in need (e.g., the Affordable Connectivity Program).
- • Participants must also be willing to participate in treatment sessions and have minimal levels of functional verbal communication (child and their caregiver must be fluent in English
- • Child must have a minimum IQ\>65 on the WASI-II at the screening/baseline visit).
- Exclusion Criteria:
- • Participants be on a stable medication regimen at least 4 weeks prior to enrollment
- • Do not have a plan to start a new psychosocial intervention (e.g., individual psychotherapy, family psychotherapy, group psychotherapy or social skills training) or behavior medication within 30 days prior to enrollment or at any point during the study. ----Participants with significant disruptive, aggressive, self-injurious or sexually inappropriate behaviors deemed potentially dangerous or overly disruptive to the group dynamic/session, having significant co-occurring neuropsychiatric illness warranting other treatment approaches as determined by study clinician (e.g., substance use disorders, psychotic disorders, schizophrenia), or having significant sensory impairment that would limit participation in intervention curriculum/materials (e.g., blindness or uncorrected hearing loss) also will be excluded.
About University Of Rochester
The University of Rochester is a leading academic institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Renowned for its commitment to excellence in education, research, and clinical practice, the university fosters a collaborative environment that integrates cutting-edge scientific inquiry with practical applications in healthcare. With a focus on diverse therapeutic areas, the University of Rochester aims to enhance treatment options and outcomes for patients while contributing to the broader scientific community through rigorous study design and ethical standards in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cincinnati, Ohio, United States
Carrboro, North Carolina, United States
Patients applied
Trial Officials
Jamie Capal, MD
Principal Investigator
University of North Carollina at Chapel Hill
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported